{"id":1777,"date":"2024-03-20T15:32:24","date_gmt":"2024-03-20T15:32:24","guid":{"rendered":"https:\/\/stoxpo.com\/?p=1777"},"modified":"2024-03-20T15:32:25","modified_gmt":"2024-03-20T15:32:25","slug":"biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\/","title":{"rendered":"BioNTech Reports Revenue Plunge as Focus Shifts to Cancer Drugs"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Shares Fall Over 9% as Biotech Giant Transitions Away from Pandemic-Era Vaccine Sales<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">BioNTech (BNTX), the pioneering biotechnology firm behind the widely-used COVID-19 vaccine developed in partnership with Pfizer, announced a significant downturn in revenue and earnings for 2023. The German-based company&#8217;s shift towards cancer drug development led to a reported plunge in revenue by over three-quarters compared to the previous year, with net profit plummeting by 90%.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Following the report, BioNTech shares experienced a sharp decline of over 9%. The company anticipates 2024 revenues to range between 2.5 billion to 3.1 billion euros, contingent upon regulatory developments and the ongoing uptake of COVID-19 vaccines. This projection marks a notable reduction from their initial forecast of approximately 3 billion euros for the same period.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">BioNTech outlined its strategic focus on oncology, aiming for its inaugural oncology launch by 2026 and targeting ten indication approvals by 2030. Despite the revenue setback, the company anticipates a return to revenue growth by 2025, as it navigates the declining trajectory of its COVID-19 vaccine business and ramps up investments in oncology.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this report:<a href=\"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/macys-opens-books-to-potential-buyers-shares-surge\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Macy\u2019s Opens Books to Potential Buyers, Shares Surge<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shares Fall Over 9% as Biotech Giant Transitions Away from Pandemic-Era Vaccine Sales BioNTech (BNTX), the pioneering biotechnology firm behind the widely-used COVID-19 vaccine developed in partnership with Pfizer, announced a significant downturn in revenue and earnings for 2023. The German-based company&#8217;s shift towards cancer drug development led to a reported plunge in revenue by [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1410,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"1","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"1","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]},"footnotes":""},"categories":[308,361],"tags":[],"coauthors":[453],"class_list":["post-1777","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","category-large-cap"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioNTech Reports Revenue Plunge as Focus Shifts to Cancer Drugs - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioNTech Reports Revenue Plunge as Focus Shifts to Cancer Drugs - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Shares Fall Over 9% as Biotech Giant Transitions Away from Pandemic-Era Vaccine Sales BioNTech (BNTX), the pioneering biotechnology firm behind the widely-used COVID-19 vaccine developed in partnership with Pfizer, announced a significant downturn in revenue and earnings for 2023. The German-based company&#8217;s shift towards cancer drug development led to a reported plunge in revenue by [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-20T15:32:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-20T15:32:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-artem-podrez-4492047-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Liliana Vida\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Liliana Vida\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\\\/\"},\"author\":{\"name\":\"Liliana Vida\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\"},\"headline\":\"BioNTech Reports Revenue Plunge as Focus Shifts to Cancer Drugs\",\"datePublished\":\"2024-03-20T15:32:24+00:00\",\"dateModified\":\"2024-03-20T15:32:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\\\/\"},\"wordCount\":191,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-artem-podrez-4492047-scaled.jpg\",\"articleSection\":[\"Biotechnology\",\"Large-Cap\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\\\/\",\"name\":\"BioNTech Reports Revenue Plunge as Focus Shifts to Cancer Drugs - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-artem-podrez-4492047-scaled.jpg\",\"datePublished\":\"2024-03-20T15:32:24+00:00\",\"dateModified\":\"2024-03-20T15:32:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-artem-podrez-4492047-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-artem-podrez-4492047-scaled.jpg\",\"width\":2560,\"height\":1440,\"caption\":\"vaccine-2\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioNTech Reports Revenue Plunge as Focus Shifts to Cancer Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\",\"name\":\"Liliana Vida\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"caption\":\"Liliana Vida\"},\"description\":\"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/stoxpo-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioNTech Reports Revenue Plunge as Focus Shifts to Cancer Drugs - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\/","og_locale":"en_US","og_type":"article","og_title":"BioNTech Reports Revenue Plunge as Focus Shifts to Cancer Drugs - Stoxpo","og_description":"Shares Fall Over 9% as Biotech Giant Transitions Away from Pandemic-Era Vaccine Sales BioNTech (BNTX), the pioneering biotechnology firm behind the widely-used COVID-19 vaccine developed in partnership with Pfizer, announced a significant downturn in revenue and earnings for 2023. The German-based company&#8217;s shift towards cancer drug development led to a reported plunge in revenue by [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\/","og_site_name":"Stoxpo","article_published_time":"2024-03-20T15:32:24+00:00","article_modified_time":"2024-03-20T15:32:25+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-artem-podrez-4492047-scaled.jpg","type":"image\/jpeg"}],"author":"Liliana Vida","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Liliana Vida","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\/"},"author":{"name":"Liliana Vida","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1"},"headline":"BioNTech Reports Revenue Plunge as Focus Shifts to Cancer Drugs","datePublished":"2024-03-20T15:32:24+00:00","dateModified":"2024-03-20T15:32:25+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\/"},"wordCount":191,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-artem-podrez-4492047-scaled.jpg","articleSection":["Biotechnology","Large-Cap"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\/","url":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\/","name":"BioNTech Reports Revenue Plunge as Focus Shifts to Cancer Drugs - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-artem-podrez-4492047-scaled.jpg","datePublished":"2024-03-20T15:32:24+00:00","dateModified":"2024-03-20T15:32:25+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-artem-podrez-4492047-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-artem-podrez-4492047-scaled.jpg","width":2560,"height":1440,"caption":"vaccine-2"},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/biontech-reports-revenue-plunge-as-focus-shifts-to-cancer-drugs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"BioNTech Reports Revenue Plunge as Focus Shifts to Cancer Drugs"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1","name":"Liliana Vida","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6","url":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","caption":"Liliana Vida"},"description":"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/stoxpo-com\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1777","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=1777"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1777\/revisions"}],"predecessor-version":[{"id":1778,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1777\/revisions\/1778"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1410"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=1777"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=1777"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=1777"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=1777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}